Diabetes Drug Might Be Tied to Increased Amputation Risk, FDA Cautions (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The FDA is investigating a potentially increased risk for leg and foot amputations among patients taking the diabetes drug canagliflozin. The sodium-glucose cotransporter-2 inhibitor is sold under the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 18, 2016 Category: Primary Care Source Type: news
FDA alert: Canagliflozin use may be associated with toe, foot amputations
Interim safety results from an ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin, according... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - May 18, 2016 Category: Endocrinology Source Type: news
FDA: Canagliflozin Linked to Amputations in Post-Marketing Trial
(MedPage Today) -- Monitoring committee suggests that CANVAS trial continue (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 18, 2016 Category: American Health Source Type: news
FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate
[5-XX-2016] The U.S. Food and Drug Administration (FDA) is alerting the public about interim safety results from an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with the diabetes medicine canagliflozin (Invokana, Invokamet). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 18, 2016 Category: Drugs & Pharmacology Source Type: news
Canagliflozin in Individuals Aged 75 and Older With T2DMCanagliflozin in Individuals Aged 75 and Older With T2DM
Is the SGLT2 inhibitor canagliflozin safe to use in elderly diabetic patients? Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2016 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
EMA Probes Link With Diabetes Drug Canagliflozin, Toe AmputationEMA Probes Link With Diabetes Drug Canagliflozin, Toe Amputation
The European Medicines Agency is reviewing the type 2 diabetes drug canagliflozin, an SGLT2 inhibitor, after an increase in toe amputations was observed in the ongoing CANVAS trial. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 15, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Canagliflozin in T1D Has Ketoacidosis Problem (CME/CE)
(MedPage Today) -- SGLT2 inhibitor effective but risky in type 1 patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 17, 2016 Category: Cardiology Source Type: news
Invokana Lawsuit News: Attorney Commentary on Canada Case
The nationally-renowned Onder Law Firm provides commentary on the latest Invokana lawsuit news; the topic is the class action lawsuit filed in Canada against Johnson & Johnson.(PRWeb October 12, 2015)Read the full story at http://www.prweb.com/releases/invokana-kidney-lawsuit/invokana-attorneys/prweb13011976.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 13, 2015 Category: Pharmaceuticals Source Type: news
First Data on SGLT2 Inhibitor Canagliflozin in Type 1 DiabetesFirst Data on SGLT2 Inhibitor Canagliflozin in Type 1 Diabetes
In a phase 2 study in type 1 diabetes, canagliflozin improved glycemic control without causing weight gain, but the risk for diabetic ketoacidosis was slightly elevated. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Invokana Lawsuit News: Attorneys React to FDA Invokana Warning
Attorneys handling national Invokana lawsuits provide commentary on the latest Invokana news, a new warning issued by the FDA; the Onder Law Firm provides timely Invokana lawsuit news and no-cost...(PRWeb September 14, 2015)Read the full story at http://www.prweb.com/releases/invokana-lawsuit-news/invokana-fda/prweb12955303.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 15, 2015 Category: Pharmaceuticals Source Type: news
FDA Warns of Fracture Risk with Diabetes Drug Canagliflozin (FREE)
By Kelly Young
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The type 2 diabetes drug canagliflozin will carry a stronger label warning about the increased risk … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 11, 2015 Category: Primary Care Source Type: news
FDA Strengthens Fracture Warning for Canagliflozin FDA Strengthens Fracture Warning for Canagliflozin
New clinical trial data for canagliflozin confirmed previously noted risk about fractures and reduced bone mineral density in the hip and spine, prompting the FDA to revise the product label. News Alerts (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 10, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Invokana May Increase Bone Fracture Risk: FDA
(MedPage Today) -- Follows evidence linking the SGLT2 inhibitor to fractures (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 10, 2015 Category: Cardiology Source Type: news
Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density
FDA added a new Warning and Precaution and revised the Adverse Reactions section of the Invokana and Invokamet drug labels. (Source: FDA MedWatch)
Source: FDA MedWatch - September 10, 2015 Category: American Health Source Type: news
Low DKA Risk Seen With Canagliflozin in Company Trials Low DKA Risk Seen With Canagliflozin in Company Trials
Janssen's analysis of data for more than 17,000 patients in its type 2 diabetes clinical-trial program for canagliflozin finds the risk for DKA is less than 1%. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 12, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
